Travere Therapeutics (Nasdaq: TVTX) has committed USD 112.5 million upfront to license civorebrutinib, a covalent reversible BTK inhibitor developed by China-based Everest Medicines (HKEX: 1952.HK), in a deal that could reach USD 1.14 billion including milestones. The exclusive licensing and collaboration agreement grants Travere development and commercialization rights for civorebrutinib across all markets outside China and certain East and Southeast Asian countries. The asset, also known as EVER001, is in Phase I/II development for primary membranous nephropathy and is being positioned for expansion into focal segmental glomerulosclerosis and minimal change disease.
Under the deal terms, Everest is eligible to receive up to approximately USD 1.03 billion in additional cash payments tied to clinical, regulatory, and commercial milestones across up to five indications. Travere will also pay tiered royalties ranging from high single-digit to double-digit percentages on annual net sales. The agreement is subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Deal context
Civorebrutinib is described by Everest as an oral, covalent reversible inhibitor of Bruton's tyrosine kinase, a signaling node within the B-cell receptor pathway. BTK inhibition suppresses B-cell activation and downstream autoantibody production — mechanisms directly implicated in immune-mediated kidney injury. In conditions such as primary membranous nephropathy, circulating anti-PLA2R autoantibodies drive podocyte damage and proteinuria; blocking BTK upstream reduces the B-cell activity responsible for generating those antibodies.
The covalent reversible binding mechanism distinguishes civorebrutinib from earlier-generation BTK inhibitors such as ibrutinib, which bind covalently and irreversibly. Reversible covalent binding is intended to maintain potency while reducing the off-target engagement associated with permanent covalent modification, though the clinical significance of this distinction in autoimmune indications remains under evaluation.
Everest presented Phase I/II data for civorebrutinib at the 62nd Congress of the European Renal Association in June 2025, reporting rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria, with high rates of immunologic and clinical remission and stable kidney function through 52 weeks. The company had previously held investor calls in November 2024 to discuss the Phase I/II data in primary membranous nephropathy. Travere plans to investigate the compound in primary membranous nephropathy, immune-mediated FSGS, and minimal change disease, with potential for additional indications.